Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

w1

Frei M, Küster L, von Krosigk PG, Koch H, Küppers. Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect. J Cardiovasc Pharmacol 1994;24(Suppl 1):S25-S28

w2

Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA 1990;263:1507-12

w3

Petersen JR, Drabaek H, Gleerup G, Mehlsen J, Petersen LJ, Winther K. ACE inhibition with spirapril improves diastolic function at rest independent of vasodilation during treatment with spirapril in mild to moderate hypertension. Angiology 1996;47:233-40

w4

Scholze J, Breitstadt A, Cairns V, Bauer B, Bender N, Priestley, et al. Ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. J Hypertens 1993;11:217-21

w5

Brown CL, Backhouse CI, Grippat JC, Santoni JP. The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects. Eur J Clin Pharmacol 1990;39:327-32

w6

Muiesan G, Agabiti-Rosei E, Buoninconti R, Cagli V, Carotti A, Corea L, et al. Antihypertensive efficacy and tolerability of captopril in the elderly: comparison with hydrochlorothiazide and placebo in a multicentre, double-blind study. J Hypertens 1987;5 (Suppl 5):S599-S602

w7

Kayanakis JG, Baulac L. Comparative study of once-daily administration of captopril 50mg, hydrochlorothiazide 25mg and their combination in mild to moderate hypertension. Br J Clin Pharmacol 1987;23 (Suppl 1):89S-92S

w8

Wing LMH, Arnolda LF, Harvey PJ, Upton J, Molloy D, Bune AJC, et al. Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly. J Hypertens 1997;15:1503-10

w9

MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med 1996;156:278-85

w10

Chalmers JP, Morris MJ, Wing LMH, Cain MD, West MJ, Graham JR, et al. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. Aust NZ J Med 1986;16:475-80

w11

Chalmers JP, Korner PI, Tiller DJ, Bune AJ, Steiner JD, West MJ, et al. Double-blind factorial trial of prindolol and hydrochlorothiazide in hypertension. Med J Aust 1976;1:650-3

w12

Chalmers J, Horvath J, Tiller D, Bune A. Effects of timolol and hydrochlorothiazide on blood-pressure and plasma renin activity. Lancet 1976;2:328-31

w13

McCorvey E, Wright JT, Culbert JP, McKenney JM, Proctor JD, Annett MP. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clinical Pharmacy 1993;12:300-5

w14

Myers MG, de Champlain J. Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension. Hypertension 1983;5:591-6

w15

Persson B, Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, an new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Eur J Clin Pharmacol 1996;50:259-64

w16

Pool J, Cushman WC, Saini RK, Nwachuku CE, Battikha JP. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens 1997;10:117-23

w17

Zachariah PK, Messerli FH, Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment. Clin Ther 1993;15:779-87

w18

Moser M, Abraham PA, Bennett WM, Brachfeld N, Goodman RP, McKenney JM, et al. The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study. Clin Pharmacol Ther 1991;49:322-9

w19

Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Human Hypertens 1998;12:861-6

w20

Canter D, Frank GJ, Knapp LE, Phelps M, Quade M, Texter M. Quinapril and hydrochlorothiazide combination for control of hypertension: assessment by factorial design. J Hum Hypertens 1994;8:155-62

w21

Fernández M, Madero R, González D, Camacho P, Villalpando J, Arriaga J. Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients. Hypertension 1994;23 (Suppl I):I-207-10

w22

Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens 1994;8:283-8

w23

Pordy RC. Cilazapril plus hydrochlorothiazide: improved efficacy without reduced safety in mild to moderate hypertension. Cardiology 1994;85:311-22

24

Weir MR, Weber MA, Punzi HA, Serfer HM, Rosenblatt S, Cady WJ. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens 1992;6:133-8

w25

Frishman WH, Burris JF, Mroczek WJ, Weir MR, Alemayehu D, Simon JS, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995;35:182-8

w26

Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med 1996;5:17-24

w27

Goldberg MR, Rockhold FW, Offen WW, Dornseif BE. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. Clin Pharmacol Ther 1989;46:208-18

w28

Pool PE, Applegate WB, Woehler T, Sandall P, Cady WJ. A randomized, controlled trial comparing diltiazem, hydrochlorothiazide, and their combination in the therapy of essential hypertension. Pharmacotherapy 1993;13:487-93

w29

Frishman WH, Bryzinski BS, Coulson LR, DeQuattro VL, Vlachakis ND, Mroczek WJ, et al. A multifactorial trial design to assess combination therapy in hypertension. Arch Intern Med 1994;154:1461-9

w30

Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999;12:797-805

w31

Jueng C, Halperin AK, Hasmimoto F, Callender K. Nifedipine GITS and hydrochlorothiazide in essential hypertension. J Clin Hypertens 1987;3:695-703

w32

Scholz D, Schwille PO, Sigel A. Double-blind study with thiazide in recurrent calcium lithiasis. J Urol 1982;128:903-7

w33

Jounela AJ, Lilja M, Lumme J, Mörlin C, Hoyem A, Wessel-aas T, et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press 1994;3:231-5

w34

Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. Arch Intern Med 1994;154:737-43

w35

Materson BJ, Oster JR, Michael UF, Bolton SM, Burton ZC, Stambaugh JE, et al. Dose response to chlorthalidone in patients with mild hypertension. Clin Pharmacol Ther 1978;24:192-8

w36

Erwteman TM, Nagelkerke N, Lubsen J, Koster M, Dunning AJ. β Blockade, diuretics, and salt restriction for the management of mild hypertension: a randomised double blind trial. BMJ 1984;289:406-9

w37

Salvetti A, Magagna A, Innocenti P, Ponzanelli F, Cagianelli A, Cipriani M, et al. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study. J Cardiovasc Pharmacol 1991;17:332-5

w38

Wing LMH, West MJ, Graham JR, Chalmers JP. Long-acting and short-acting diuretics in mild essential hypertension. Clin Exp Hypertens 1982;A4:1429-41

w39

Bateman DN, Dean CR, Mucklow JC, Bulpitt CJ, Dollery CT. Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol 1979;7:357-63

w40

Morledge JH, Ettinger B, Aranda J, BcBarron F, Barra P, Gorwit J, et al. Isolated systolic hypertension in the elderly. A placebo-controlled, dose-response evaluation of chlorthalidone. J Am Geriatr Soc 1986;34:199-206

w41

Cranston WI, Juel-Jensen BE. The effects of spironolactone and chlorthalidone on arterial pressure. Lancet 1962;1:1161-4

w42

Ferrara LA, de Simone G, Mancini M, Fasano ML, Pasanisi F, Vallone G. Changes in left ventricular mass during a double-blind study with chlorthalidone and slow-release nifedipine. Eur J Clin Pharmacol 1984;27:525-8

w43

Durel LA, Hayashi PJ, Weidler DJ, Schneiderman N. Effectiveness of antihypertensive medications in office and ambulatory settings: a placebo-controlled comparison of atenolol, metoprolol, chlorthalidone, verapamil, and an atenolol-chlorthalidone combination. J Clin Pharmacol 1992;32:564-70

w44

Bradley K, Flack JM, Belcher J, Elmer P, Miller P, Grimm R. Chlorthalidone attenuates the reduction in total cholesterol and small, dense LDL cholesterol subclass associated with weight loss. Am J Hypertens 1993;6:636-9

w45

Moser M. Low-dose diuretic therapy for hypertension. Clin Ther 1986;8:554-62

w46

McFate Smith WM, Feigal DW, Furberg CD, Greenlick M, Kuller L, Perry HM, et al. Use of diuretics in treatment of hypertension in the elderly. Drugs 1986;31:154-64

w47

Hall WD, Weber MA, Ferdinand K, Flamenbaum W, Marbury T, Jain AK, et al. Lower dose diuretic therapy in the treatment of patients with mild to moderate hypertension. J Hum Hypertens 1994;8:571-5

w48

Schaller M, Waeber B, Brunner HR. Double-blind comparison of indapamide with a placebo in hypertensive patients treated by practicing physicians. Clin Exp Hypertens 1985;A7:985-94

w49

Fiddes R, Blumenthal J, Dawson JE, Dyckman E, Hammond PGS, Harris S, et al. Evaluation of indapamide 1.25mg once daily in elderly patients with mild to moderate hypertension. J Hum Hypertens 1997;11:239-44

w50

Borghi L, Meschi T, Guerra A, Novarini A. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993;22 (Suppl 6):S78-S86

w51

Chalmers JP, Wing LMH, Grygiel JJ, West MJ, Graham JR, Bune AJ. Effects of once daily indapamide and pindolol on blood pressure, plasma aldosterone concentration and plasma renin activity in a general practice setting. Eur J Clin Pharmacol 1982;22:191-6

w52

Taylor DR, Constable J, Sonnekus M, Milne FJ. Effect of indapamide on serum and red cell cations, with and without magnesium supplementation, in subjects with mild hypertension. S Afr Med J 1988;74:272-6

w53

Weidler D, Jallad NS, Curry C, Ferdinand K, Jain AK, Schnaper HW, et al. Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension. J Clin Pharmacol 1995;35:45-51

w54

Ambrosioni E, Safar M, Degaute JP, Malin PL, MacMahon M, Pujol DR, et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. J Hypertens 1998;16:1677-84

w55

Myers MG, Asmar R, Leenen FHH, Safar M. Fixed low-dose combination therapy in hypertension – a dose response study of perindopril and indapamide. J Hypertens 2000;18:317-25

w56

Carlsen JE, Køber L, Torp-Pedersen, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990;300:975-8

w57

Christiansen C, Christensen MS, Hagen C, Stocklund KE, Transbøl I. Effects of natural estrogen/gestagen and thiazide on coronary risk factors in normal postmenopausal women. Acta Obstet Gynecol Scand 1981;60:407-412

w58

Horvath JS, Caterson RJ, Collett P, Duggin GG, Kelly DH, Tiller DJ. Labetalol and bendrofluazide: comparison of their antihypertensive effects. Med J Aust 1979;1:626-8

w59

Webster J, Dollery CT, Hensby CN. Circulating prostacyclin concentrations may be increased by bendrofluazide in patients with essential hypertension. Clin Sci 1980;59 (Suppl 6):125s-128s

w60

Wilcox RG. Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. BMJ 1978;2:383-5

w61

Curry CL, Harris R, MacKay JH, Nugent CA, Ryan J, Schnaper, et al. Clinical studies of a new, low-dose formulation of metolazone for the treatment of hypertension. Clin Ther 1986;9:47-62

w62

Fernandez PG, Zachariah PK, Bryant DG, Missan SS. Antihypertensive efficacy of α -methyldopa, chlorothiazide and Supres-150 (α -methyldopa-chlorothiazide). Can Med Assoc J 1980;123:284-7

w63

McVeigh G, Galloway D, Johnston D. The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. BMJ 1988;297:95-8

w64

Chrysant SG, Chappel C, Farnham J, Levin B, Lueg M, McCluskey D, et al. Antihypertensive and metabolic effects of single and combined atenolol regimens. J Clin Pharmacol 1992;32:61-65

w65

Vanhees L, Fagard R, Lijnen P, Amery A. Effect of antihypertensive medication on endurance exercise capacity in hypertensive sportsmen. J Hypertens 1991;9:1063-8

w66

Verdecchia P, Gatteschi C, Benemio G, Boldrini F, Guerrieri M, Porcellati C. Duration of the antihypertensive action of atenolol, enalapril and placebo. Int J Clin Pharmacol Ther Toxicol 1988;26:570-4

w67

Gostick NK, Mayhew SR, Million R, Sagar D, Suxena SR, Igram DF, et al. A dose-response study of atenolol in mild to moderate hypertension in general practice. Curr Med Res Opin 1977;5:179-84

w68

Cilliers AJ. Atenolol as primary therapy in previously untreated hypertensives and as an adjuvant to other therapy. S Afr Med J 1979;55:321-4

w69

Baez MA, Garg DC, Jallad NS, Weidler DJ. Antihypertensive effect of doxazosin in hypertensive patients: comparison with atenolol. Br J Clin Pharmacol 1986;21 (Suppl 1):63S-67S

w70

Maclean D, Mitchell ET, Lewis R, Irvine N, McLay S, McEwen J, et al. Comparison of once daily atenolol, nitrendipine and their combination in mild to moderate essential hypertension. Br J Clin Pharmacol 1990;29:455-63

w71

Van Nueten L, Taylor FR, Robertson JIS. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens 1998;12:135-40

w72

Hansson L, Åberg H, Karlberg BE, Westerlund A. Controlled study of atenolol in treatment of hypertension. BMJ 1975;2:367-70

w73

Lange-Andersen KL, Ottmann W, Piatkowski W, Green KA. Working ability and exercise tolerance during treatment of mild hypertension. Int Arch Occup Environ Health 1985;56:49-55

w74

Tonkin AL, Wing LMH, Russell AE, West MJ, Bune AJC, Morris MJ, et al. Diltiazem and atenolol in essential hypertension: additivity of effects on blood pressure and cardiac conduction with combination therapy. J Hypertens 1990;8:1015-8

w75

Streufert S, DePadova A, McGlynn T, Pogash R, Piasecki M. Impact of β -blockade on complex cognitive functioning. Am Heart J 1988;116:311-4

w76

Wing LMH, Chalmers JP, West MJ, Russell AE, Morris MJ, Cain MD. Enalapril and atenolol in essential hypertension: attenuation of hypertensive effects in combination. Clin Exp Hypertens 1988;10:119-33

w77

Ekbom T, Dahlöf B, Hansson L, Lindholm LH, Scherstén B, Wester P. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens 1991;10:1525-9

w78

Saul P, Jones BP, Edwards KG, Tweed JA. Randomized comparison of atenolol and placebo in the treatment of anxiety: a double-blind study. Eur J Clin Pharmacol 1985;28:109-110

w79

Lyons D, Fowler G, Webster J, Hall ST, Petrie JC. An assessment of lacidipine and atenolol in mild to moderate hypertension. Br J Clin Pharmacol 1994;37:45-51

w80

Tötterman K, Groop L, Groop P, Kala R, Tolppanen, Fyhrquist F. Effect of beta-blocking drugs on beta-cell function and insulin sensitivity in hypertensive non-diabetic patients. Eur J Clin Pharmacol 1984;26:13-7

w81

Jeffers TA, Webster J, Petrie JC. Atenolol once-daily in hypertension. Br J Clin Pharmacol 1977;4:523-7

w82

Clement DL, Bogaert MG, Pannier R. Effect of beta-adrenergic blockage on blood pressure variation in patients with moderate hypertension. Eur J Clin Pharmacol 1977;11:325-7

w83

Clement DL, De Pue NY, Packet L. Effect of calcium antagonists on ambulatory blood pressure and its variations. J Cardiovasc Pharmacol 1987;10 (Suppl 10):S117-S119

w84

Petrie C, Jeffers TA, Robb OJ, Scott AK, Webster J. Atenolol, sustained-release oxprenolol, and long-acting propranolol in hypertension. BMJ 1980;1:1573-4

w85

Houston MC, Burger C, Hays JT, Nadeau J, Swift L, Bradley CA, et al. The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J 1990;120:172-9

w86

Roberts DH, Tsao Y, MCLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2:650-3

w87

Wilcox RG, Hampton JR. Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. Br Heart J 1981;46:498-502

w88

Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991;303:1100-4

w89

Broekman CPM, Haensel SM, Ven de Ven LLM, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther 1992;18:325-31

w90

Van de Ven LLM, Mouthaan BJ, Hoes MJ. Treatment of hyperventilation syndrome with bisoprolol: a placebo-controlled clinical trial. J Psychosom Res 1995;39:1007-13

w91

Tseng C, Chiang F, Hsu K, Tseng Y, Hu W, Chen J, et al. Short-term efficacy and safety of bisoprolol in treatment of patients with mild-to-moderate hypertension - A two-center, double-blind study in Taiwan. Acta Cardiologica Sinica 1993;9:155-60

w92

Davidov ME, Singh SP, Vlachakis ND, Blumenthal JB, Simon JS, Bryzinski JS, et al. Bisoprolol, a once-a-day beta-blocking agent for patients with mild to moderate hypertension. Clin Cardiol 1994;17:263-268

w93

Asmar RG, Kerihuel JC, Girerd XJ, Safar ME. Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension. Am J Cardiol 1991;68:61-4

w94

Williams RL, Goyle KK, Herman TS, Rofman BA, Ruoff GE, Hogan LB. Dose-dependent effects of betaxolol in hypertension: a double-blind multicenter study. J Clin Pharmacol 1992;32:360-7

w95

Ameling EH, de Korte DF, Man in ’t Veld AJ. Impact of diagnosis and treatment of hypertension on quality of life: a double-blind, randomized, placebo-controlled, cross-over study of betaxolol. J Cardiovasc Pharmacol 1991;18:752-60

w96

Salonen JT, Palminteri R. Comparison of two doses of betaxolol and placebo in hypertension: a randomised, double-blind cross-over trial. Eur J Clin Pharmacol 1982;23:491-4

w97

Gudbjornsdottir S, Fowelin J, Elam M, Attvall S, Bengtsson BA, Marin P, et al. The effect of metoprolol treatment on insulin sensitivity and diurnal plasma hormome levels in hypertensive subjects. Eur J Clin Invest 1997;27;29-35

w98

Groop L, Tötterman KJ, Harno K, Gordin A. Influence of beta-blocking drugs on glucose metabolism in hypertensive, non-diabetic patients. Acta Med Scand 1983;213:9-14

w99

Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in non-obese men. J Intern Med 1994;235:335-41

w100

Jäättelä A, Baandrup S, Houtzagers J, Westergren G. The efficacy of low dose metoprolol CR/ZOK in mild hypertension and in elderly patients with mild to moderate hypertension. J Clin Pharmacol 1990;30 (Suppl):S66-S71

w101

Lepäntalo MJA, Tötterman KJ. Lower limb haemodynamics during antihypertensive treatment with metoprolol and propranolol. Int Angiol 1985;4:225-8

w102

MacMahon S, MacDonald GJ, Bernstein L, Andrews G, Blacket RB. Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985;1:1233-6

w103

Reybrouck T, Amery A, Fagard R, Jousten P, Lijnen P, Meulepas E. Beta-blockers: once or three times a day? BMJ 1978;1:1386-8

w104

Vandongen R, Margetts B, Deklerk N, Beilin LJ, Rogers P. Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol. Br J Clin Pharmacol 1986;21:627-32

w105

Trafford JAP, Latta D, Little PS, Parsley J, Ankier SI. A multi-centre, placebo controlled comparative study between 200 mg and 400 mg celiprolol in patients with mild to moderate essential hypertension. Curr Med Res Opin 1989;11:550-6

w106

Kimura S, DeQuattro V, Hernandez PH, Lee DD. Effects of celiprolol on plasma renin, aldosterone, norepinephrine and epinephrine in primary hypertension. Am J Cardiol 1988;62:751-4

w107

Watson RDS, Stallard TJ, Littler WA. Comparison of once and twice daily administration of acebutolol in hypertension. Br J Clin Pharmacol 1980;9:209-12

w108

Van Nueten L, Dupont AG, Vertommen C, Goyvaerts H, Robertson JIS. A dose-response trial of nebivolol in essential hypertension. J Hum Hypertens 1997;11:139-44

w109

Himmelmann A, Hedner T, Ssnoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996;51:259-64

w110

van Merode T, van Bortel L M, Smeets FA, Mooij JM, Bohm RO, Rahn KH, et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens 1989;7 (suppl 6):S262-3

w111

Glassock RJ, Weitzman RE, Bennett CM, Maxwell M, Hamilton B, Winer N, et al. Pindolol: effects on blood pressure and plasma renin activity. Am Heart J 1982;104:421-5

w112

Hamilton BP, Hamilton J, Kirkendall WM. Pulmonary function in hypertensive patients treated with pindolol: a report of two studies. Am Heart J 1982;104:432-7

w113

Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren DA, et al. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999;45:1170-7

w114

Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study. J Clin Psychopharmacol 1998;18:441-6

w115

Pearson RM, Bulpitt CJ, Havard CWH. Biochemical and haematological changes induced by tienilic acid combined with propranolol in essential hypertension. Lancet 1979;1:697-9

w116

Dargie H, Cleland J, Findlay I, Murray G, McInnes G. Combination of verapamil and beta-blockers in systemic hypertension. Am J Cardiol 1986;57:80D-82D

w117

McInnes GT, Findlay IN, Murray G, Cleland JGF, Dargie HJ. Cardiovascular responses to verapamil and propranolol in hypertensive patients. J Hypertens 1985;3 (Suppl 3):S219-21

w118

Galloway DB, Glover SC, Hendry WG, Logie AW, Petrie JC, Smith MC, et al. Propranolol in hypertension: a dose-response study. BMJ 1976;2:140-2

w119

Hudson CFE. An evaluation of once daily long acting propranolol hydrochloride (Inderal LA and Half-Inderal LA) in the treatment of anxiety. A double-blind placebo-controlled general practice study. Br J Clin Pract 1988;42:419-26

w120

Moleur P, Peyrieux JC, Luciani J, David D, Boissel JP. Bopindolol in the treatment of moderate hypertension: a dose-response study. Fundam Clin Pharmacol 1988;2:431-40

w121

Adsett CA, Bellissimo A, Mitchell A, Wilczynski N, Haynes RB. Behavioral and physiological effects of a beta-blocker and relaxation therapy on mild hypertensives. Psychosom Med 1989;51:523-6

w122

Dupont AG, Vanderniepen P, Bossuyt AM, Jonckheer MH, Six RO. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function. Br J Clin Pharmacol 1985;20:93-99

w123

Casadei B, Conway J, Coats AJS, Bird R. Antihypertensive effect of carvedilol: a preliminary dose-response study. Clinical Investigigator 1992;70 (Suppl):S37-S38

w124

Dupont AG, Van der Niepen P, Taeymans Y, Ingels M, Piepsz A, Bossuyt AM, et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987;10 (Suppl 11):S130-S136

w125

Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Eng J Med 1998;338:784-90

w126

Chrysant SG, Brown RD, Kem DC, Brown JL. Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril. Clin Pharmacol Ther 1983;33:741-6

w127

Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1987;23:652-7

w128

Küppers HE, Jäger BA, Luszick JH, Gräve, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997;15:93-7

w129

Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM. Enalapril effects on alcohol intake and other consummatory behaviors in alcoholics. Clin Pharmacol Ther 1991;50:96-106

w130

Forette F, Handfield-Jones R, Henry-Amar M, Fouchard M, Bouchacourt P, Hervy M, et al. Rationale for ACE inhibition in the elderly: treatment of arterial hypertension with enalapril. Gerontology 1987;33:9-16

w131

van Baak MA, Mooij JMV, Wijnen JAG, Tan FS. Submaximal endurance exercise performance during enalapril treatment in patients with essential hypertension. Clin Pharmacol Ther 1991;50:221-7

w132

Bergstrand R, Herlitz H, Johansson S, Berglund G, Vedin A, Wilhelmsson C, et al. Effective dose range of enalapril in mild to moderate essential hypertension. Br J Clin Pharmacol 1985;19:605-11

w133

Gibbs JSR, Crean PA, Mockus L, Wright C, Sutton G, Fox KM. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina. Br Heart J 1989;62:112-7

w134

Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. Am J Hypertens 1989;2:352-4

w135

Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 1997;79:431-5

w136

Cushman WC, Cohen JD, Jones RP, Marbury TC, Rhoades RB, Smith LK. Comparison of the fixed combination of enalapril/diltiazem ER and their monotherapies in stage 1 to 3 essential hypertension. Am J Hypertens 1998;11:23-30

w137

Whelton A, Dunne B, Glazer N, Kostis JB, Miller WE, Rector DJ, et al. Twenty-four hour blood pressure effect of once-daily lisinopril, enalapril, and placebo in patients with mild to moderate hypertension. J Hum Hypertens 1992;6:325-31

w138

Levine JH, Ferdinand KC, Cargo P, Laine H, Lefkowitz M. Additive effects of verapamil and enalapril in the treatment of mild to moderate hypertension. Am J Hypertens 1995;8:494-9

w139

Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147-51

w140

Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-50

w141

Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6

w142

Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46

w143

Smith DHG, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000;40:1380-90

w144

Franke H. Antihypertensive effects of candesartan cilexetil, enalapril and placebo. J Hum Hypertens 1997;11 (Suppl 2):S61-62

w145

Simon G, Morioka S, Snyder DK, Cohn JN. Increased renal plasma flow in long-term enalapril treatment of hypertension. Clin Pharmacol Ther 1983;34:459-65

w146

Sassano P, Chatellier G, Alhenc-Gelas F, Corvol P, Menard J. Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension. Am J Med 1984;77(suppl 2A):18-22

w147

Bilan A, Chibowska M, Palusinski R, Witczak, Ostrowski S, Makaruk B, et al. Enalapril (10 mg/day) in systemic sclerosis. Adv Exp Med Biol 1999;455:285-8

w148

Applegate WB, Cohen JD, Wolfson P, Davis A, Green S. Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension. Am J Cardiol 1996;78:51-5

w149

Gerritsen TA, Bak AAA, Stolk RP, Jonker JJC, Grobbee DE. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension. J Hypertens 1998;16:689-96

w150

Morgan TO, Morgan O, Anderson A. Effect of dose on trough peak ratio of antihypertensive drugs in elderly hypertensive males. Clin Exp Pharmacol Physiol 1995;22:778-80

w151

Nankervis A, Nicholls K, Kilmartin G, Allen P, Ratnaike S, Martin FIR. Effects of perindopril on renal histomorphometry in diabetic subjects with microalbuminuria: a 3-year placebo-controlled biopsy study. Metabolism 1998;47 (suppl 1):12-15

w152

Luccioni R, Frances Y, Gass R, Gilgenkrantz JM. Evaluation of the dose-effect relationship of perindopril in the treatment of hypertension. Clin Exp Hypertens 1989;A11:521-34

w153

West JNW, Smith SA, Stallard TJ, Littler WA. Effects of perindopril on ambulatory intra-arterial blood pressure, cardiovascular reflexes and forearm blood flow in essential hypertension. J Hypertens 1989;7:97-104

w154

Louis WJ, Workman BS, Conway EL, Worland P, Rowley K, Drummer O, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J Cardiovasc Pharmacol 1992;20:505-11

w155

Chrysant SG, McDonald RH, Wright JT, Barden PL, Weiss RJ. Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. Clin Pharmacol Ther 1993;53:479-84

w156

Myers MG. A dose-response study of perindopril in hypertension: effects on blood pressure 6 and 24h after dosing. Am J Cardiol 1996;12:1191-6

w157

Overlack A, Adamczak M, Bachmann W, Bönner G, Bretzel RG, Derichs R, et al. ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. Am J Med 1994;97:126-34

w158

Cheung R, Lewanczuk RZ, Rodger NW, Huff MW, Oddou-Stock P, Botteri F, et al. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy. Int J Clin Pract 1999;53:584-92

w159

Salvetti A, Innocenti PF, Iardella M, Pambianco F, Saba GC, Rossetti M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a crossover study. J Hypertens 1987;5 (Suppl 4):S139-S142

w160

Schoenberger JA, Wilson DJ. Once-daily treatment of essential hypertension with captopril. J Clin Hypertens 1986;4:379-87

w161

Conway J, Way B, Boon N, Somers V. Is the antihypertensive effect of captopril influenced by the dosage frequency? A study with ambulatory monitoring. J Hum Hypertens 1988;2:123-6

w162

Lavessaro G, Ladetto PE, Valente M, Stramignoni D, Zanna C, Assogna G, et al. Ketanserin and captopril interaction in the treatment of essential hypertensives. Cardiovasc Drugs Ther 1990;4:119-22

w163

Veterans Administration Cooperative Study Group on Antihypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Arch Intern Med 1984;144:1947-53

w164

Salvetti A, Circo A, Raciti S, Gulizia M, Cardillo R, Miceli S, et al. Captopril at 50mg as well as at 100mg once a day reduces blood pressure for up to 24h: a double-blind randomized crossover study in mild to moderate hypertensives. J Hypertens 1988;6 (Suppl 4):S666-S668

w165

Wiggam MI, Hunter SJ, Atkinson AB, Ennis CN, Henry JS, Browne JN, et al. Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens 1998;16:1651-7

w166

Drayer JIM, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 1983;5 (Suppl III):III108-13

w167

Insua A, Ribstein J, Mimran A. Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Postgrad Med J 1988;64 (Suppl 3):59-62

w168

Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. Hypertension 1995;26:124-30

w169

Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978-81

w170

DeQuattro V, Lee D. Fixed-dose combination therapy with trandolapril and verapamil SR is effective in primary hypertension. Am J Hypertens 1997;10 (Suppl):138S-145S

w171

Veratran Study Group. Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure. Am J Hypertens 1997;10:492-9

w172

De Bruijn JHB, Orofiamma BA, Pauly NC. Efficacy and tolerance of trandolapril (0.5-2mg) administered for 4 weeks in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994;23 (Suppl 4):S60-S64

w173

Messerli F, Frishman WH, Elliott WJ. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens 1998;11:322-7

w174

Pritchard G, Lyons D, Webster J, Petrie JC, MacDonald TM. Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? Br J Clin Pharmacol 1997;44:145-9

w175

Kohlmann O , Jardim PCBV, Oigman W. Brazilian multicenter on efficacy and tolerability in mild-to-moderate essential arterial hypertension. EMBATHE substudy with ambulatory blood pressure monitoring. Arq Bras Cardiol 1999;72:553-7

w176

Mancia G, De Cesaris R, Fogari R, Lattuada S, Montemurro G, Palombo C, et al. Evaluation of the antihypertensive effect of once-a-day trandolapril by 24-hour ambulatory blood pressure. Am J Cardiol 1992;70:60D-66D

w177

Scholze J, Zilles P, Compagnone D. Verapamil SR and trandolapril combination therapy in hypertension—a clinical trial of factorial design. Br J Clin Pharmacol 1998;45:491-5

w178

Mroczek WJ, Klein J, Burris JF. Dose-finding study of cilazapril (inhibace) in patients with uncomplicated essential hypertension. Clin Exp Hypertens 1991;A13:1415-32

w179

Prager G, Klein P, Schmitt M, Prager R. Antihypertensive efficacy of cilazapril 2.5 and 5.0mg once-daily versus placebo on office blood pressure and 24-hour blood pressure profile. J Cardiovasc Pharmacol 1994;24 (Suppl 3):S93-S99

w180

Kobrin I, Güntzel P, Viskoper R, Paran E, Zimlichman R. Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension. Drugs 1991;41:31-6

w181

Güntzel P, Kobrin I, Pasquier C, Zimlichman R, Viskoper JR. The effect of cilazapril, a new angiotensin converting enzyme inhibitor, on peak and trough blood pressure measurements in hypertensive patients. J Cardiovasc Pharmacol 1991;17:8-12

w182

Lacourcière Y, Leenen F, Rangno R, Spence JD, Lenis JH, Myers MG. Discrepancies between clinic and ambulatory blood pressure responses to cilazapril therapy. Can J Cardiol 1994;10:605-10

w183

Fernandez PG, Bolli P, Lee C. The 24h blood pressure responses of hypertensives to a once-a-day cilazapril regimen. Can J Cardiol 1990;6:53-8

w184

Krum H, Jackson B, Conway EL, Howes LG, Johnston CI, Louis WJ. Steady-state pharmacokinetics and pharmacodynamics of cilazapril in the presence and absence of cyclopenthiazide. J Cardiovasc Pharmacol 1992;20:451-7

w185

White WB, McCabe EJ, Hager WD, Schulman P. The effects of the long-acting angiotensin-converting enzyme inhibitor cilazapril on casual, exercise and ambulatory blood pressure. Clin Pharmacol Ther 1988;44 (Suppl 3):173-8

w186

Poirier L, Pyzyk M, Provencher P, Lacourciére. Comparative effects of 2.5 and 5mg cilazapril versus placebo on daily blood pressure load. Am J Hypertens 1991;4:913-5

w187

Burris JF. The effect of ramipril on ambulatory blood pressure: a multicenter study. J Cardiovasc Pharmacol 1991;18 (Suppl 2):S131-3

w188

McCarron D. 24-hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Clin Cardiol 1991;14:737-42

w189

Schnaper HW. Dose-response relationship of ramipril in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1991;18 (Suppl 2):S128-S130

w190

Homuth V, Faulhaber H, Loose U, Löffler K, Luft FC. Usefulness of piretanide plus ramipril for systemic hypertension: a multicenter trial. Am J Cardiol 1993;72:666-71

w191

Villamil AS, Cairns V, Witte PU, Bertolasi CA. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo. Am J Cardiol 1987;59:110D-114D

w192

Kahan T, Eliasson K. The influence of long-term ACE inhibitor treatment on circulatory responses to stress in human hypertension. Am J Hypertens 1999;12:1188-94

w193

Scholze J, Bauer B, Massaro J. Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. Clin Exp Hypertens 1999;21:1447-62

w194

Chan P, Lin C, Tomlinson B, Lin T, Lee Y. Additive effects of diltiazem and lisinopril in treatment of elderly patients with mild-to-moderate hypertension. Am J Hypertens 1997;10:743-9

w195

Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997;11:483-9

w196

Thürig C, Böhlen L, Schneider M, de Courten M, Shaw SG, Riesen W, et al. Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients. Eur J Clin Pharmacol 1995;49:21-6

w197

Paolisso G, Balbi V, Gambardella A, Varricchio G, Tortoriello R, Saccomanno F, et al. Lisinopril administration improves insulin action in aged patients with hypertension. J Hum Hypertens 1995;9:541-6

w198

Tomei R, Rossi L, Carbonieri E, Franceschini L, Molon G, Zardini P. Antihypertensive effect of lisinopril assessed by 24-hour ambulatory monitoring: a double-blind, placebo-controlled, cross-over study. J Cardiovasc Pharmacol 1992;19:911-14

w199

Polónia J, Martins L, Macedo F, Faria DB, Simões, Brandão F, et al. Lisinopril and diltiazem reduce left ventricular mass without changing blood pressure in normotensive subjects with exaggerated blood pressure response to exercise. Rev Port Cardiol 1996;15:185-93

w200

Gomez JH, Cirillo VJ, Sromovsky JA, Otterbein ES, Shaw WC, Rush JE, et al. Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 1989;28:415-20

w201

Cuspidi C, Lonati L, Sampieri L, Leonetti G, Muiesan ML, Agabiti-Rosei E, et al. Lack of effect of short-term lisinopril administration on left ventricular filling dynamics in hypertensive patients with diastolic dysfunction. Blood Pressure 1997;6:307-12

w202

Lee AFC, Dick JBC, Bonnar CE, Struthers AD. Lisinopril improves arterial function in hyperlipidaemia. Clin Sci 1999;96:441-8

w203

Maclean D. Quinapril: a double-blind, placebo-controlled trial in essential hypertension. Angiology 1989;40:370-81

w204

Säynävälammi P, Pörsti I, Pörsti P, Nurmi A, Seppälä E, Manninen V, et al. Effects of the converting enzyme inhibitor quinapril on blood pressure, renin-angiotensin system and prostanoids in essential hypertension. J Cardiovasc Pharmacol 1988;12:88-93

w205

Gupta RK, Kjeldsen SE, Motley E, Weder AB, Sweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol 1991;17:13-9

w206

Kjeldsen SE, Gupta RK, Krause L, Weder AB, Julius S. Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril. Am Heart J 1992;123:1433-8

w207

Kontopoulos AG, Athyros VG,Didangelos TP, Papageorgiou AA, Avramidis MJ, Mayroudi MC, et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355-361

w208

Ford NF, Fulmor IE, Nichola PS, Alpin PG, Herron JM. Fosinopril monotherapy: relationship between blood pressure reduction and time of administration. Clin Cardiol 1993;16:324-30

w209

Anderson RJ, Duchin KL, Gore RD, Herman TS, Michaels RS, Nichola PS, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 1991;17:636-42

w210

Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II. Clin Ther 1990;12:520-33

w211

Guitard C, Lohmann FW, Alfiero R, Ruina M, Alvisi V. Comparison of efficacy of spirapril and enalapril in control of mild-to-moderate hypertension. Cardiovasc Drugs Ther 1997;11:449-57

w212

Guitard C, Sasssano P, Tzincoca C, Duchiez J, Safar ME. Placebo-controlled crossover comparison of spirapril at 3, 6, 12 and 24 mg once daily in mild to severe essential hypertension. Blood Press 1994;3 (suppl 2):61-8

w213

Guitard C, Alvisi V, Maibach E, Franck J, Cocco G, Boxho G, et al. Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension. Blood Press 1994;3 (suppl 2):81-7

w214

Fairhurst GJ. A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. Blood Press 1994;3 (suppl 2):77-80

w215

Frishman WH, Ram CVS, McMahon FG, Chrysant SG, Graff A, Kupiec JW, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. J Clin Pharmacol 1995;35:1060-6

w216

Kuschnir E, Acuña E, Sevilla D, Vasquez J, Bendersky M, Resk J, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 10 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 1996;18:1213-24

w217

Koch B, Oparil S, Stimpel M. Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women. J Human Hypertens 1999;13:337-42

w218

Fridman K, Wysocki M, Friberg P, Andersson OK. Candesartan cilexetil and renal hemodynamics in hypertensive patients. Am J Hum Hypertens 2000;13:1045-8

w219

Christensen PK, Lund S, Parving H-H. Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients. Kidney Int 2001;60:1435-42

w220

Heuer HJ, Schöndorfer G, Högemann AM. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997;11:S55-6

w221

Meineke I, Feltkamp H, Högemann A, Gundert-Remy U. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - a population analysis. Eur J Clin Pharmacol 1997;53:221-8

w222

Elmfeldt D, George M, Hűbner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin-II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997;11:S49-53

w223

Farsang C, Kawecka-Jaszcz K, Langan J, Maritz F, Zannad F. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001;21:17-23

w224

Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. Am J Hypertens 1999;12:1181-7

w225

Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin-II antagonist, in comparison with losartan. Blood Press 1998;7:53-9

w226

Reif M, White WB, Fagan TC, Oparil S, Flanagan TL, Edwards DT, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol 1998;82:961-5

w227

Bell TP, DeQuattro V, Lasseter KC, Ruff D, Hardison JD, Cushing D, et al. Effective dose range of candesartan cilexetil for systemic hypertension. Am J Cardiol 1999;83:272-5

w228

Zuschke CA, Keys I, Munger MA, Carr AA, Marinides GN, Flanagan TL, et al. Candesartan cilexetil: comparison of once-daily versus twice-daily administration for systemic hypertension. Clin Ther 1999;21:464-74

w229

Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, et al. A comparison of angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999;12:414-7

w230

Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810

w231

Neutel J, Weber M, Pool J, Smigh D, Fitzsimmons S, Chiang Y-T, et al. Valsartan, a new angiotensin-II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997;19:447-58

w232

Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 1998;20:1106-15

w233

Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin-II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53

w234

Mallion M, Siche JP, Lacourcière Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin-II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999;13:657-64

w235

Paolisso G, Tagliamonte MR, Gambardella A, Manzella D, Gualsiero P, Varricchio G, et al. Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997;11:307-12

w236

Fagard R, Lijnen P, Pardaens K, Thijs L, Vinck W. A randomised, placebo-controlled, double-blind, crossover study of losartan and enalapril in patients with essential hypertension. J Hum Hypertens 2001;15:161-7

w237

Cheetham C, O’Driscoll G, Standon K, Taylor R, Green D. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type II diabetes. Clin Sci 2001;100:13-7

w238

Pancera P, Persciuttini B, Sansone S, Montagna L, Paluani F, Covi G, et al. Effect of losartan on heart rate and blood pressure variability during tilt test and trinitroglycerine vasodilation. J Hypertens 1999;17:513-21

w239

Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995;13:S29-33

w240

Ikeda LS, Harm SC, Arcuri KE, Goldberg AI, Sweet CS. Comparative antihypertensive effects of losartan 50mg and losartan 50mg titrated to 100mg in patients with essential hypertension. Blood Press 1997;6:35-43

w241

Pűchler K, Laeis P Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin-II antagonist. J Hypertens 2001;19:S41-8

w242

Pool JL, Glazer R, Chiang Y-T, Gatlin M. Dose-response efficacy of valsartan, a new angiotensin-II receptor blocker. J Hum Hypertens 1999;13:275-81

w243

Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G. Efficacy and tolerability of irbesartan, an angiotensin-II receptor antagonist, in primary hypertension. Clin Drug Invest 1998;3:217-27

w244

Fogari R, Ambrosoli S, Corradi L, Esposti ED, Mos L, Nami R, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hum Hypertens 1997;15:1511-8

w245

Pool JL, Guthrie RM, Littlejohn TW, Raskin P, Shephard AMM, Weber A, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11:462-70

w246

Benetos A, Gautier S, Laflèche A, Topouchian Jm Frangin G, Girerd X, et al. Blockade of angiotensin II type 1 receptors: effect on carotid and radial artery structure and function in hypertensive humans. J Vasc Res 2000;37:8-15

w247

McGill JB, Reilly P. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomised double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001;23:833-50

w248

Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT₁ receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Therapy 1998;15:206-17

w249

Neutel JM, Buckalew V, Chrysant SG, Mroczek WJ, Ruff DA, Weber M. Efficacy and tolerability of tasosartan, a novel angiotensin-II receptor blocker: results from a 10-week, double-blind, placebo controlled, dose-titration study. Am Heart J 1999;137:118-25

w250

Feldman R, Chattman MS, Lonigro A, Sievers RJ. Tasosartan in patients with essential hypertension: a randomized, double-blind, dose-titration study. Adv Therapy 1997;14:290-303

w251

Rhéaume C, Waib PH, Lacourcière Y, Cléroux J. Effects of angiotensing antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. J Hypertens 1998;16:2085-9

w252

Lacourcière Y, Pool JL, Svetkey L, Gradman AH, Larochelle P, de Champlain J, et al. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Am J Hypertens 1998;11:454-61

w253

Gradman AH, Gray J, Maggiacomo F, Punzi H, White WB. Assessment of once-daily eprosartan, an angiotensin-II antagonist, in patients with systemic hypertension. Clin Ther 1999;21:442-53

w254

Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. J Hypertens 1999;17:129-36

w255

White WB, Anwar YA, Mansoor GA, Sica DA. Evaluation of the 24-hour blood pressure effects of eprosartan in patients with systemic hypertension. Am J Hypertens 2001;14:1248-55

w256

Schmitz A, Pedersen MM, Mogensen CE. Effects of felodipine on urinary albumin excretion and metabolic control in hypertensive non-insulin-dependent diabetics. Am J Hypertens 1990;3:611-617

w257

Campbell LM, Cowen KJ, Cranfield FR, Goves JR, Jones DF, Lees CTW, et al. Felodipine-ER once daily as monotherapy in hypertension. J Cardiovasc Pharmacol 1990;15:569-573

w258

Cooperative Study Group. Felodipine, a new calcium antagonist, as monotherapy in mild or moderate hypertension. Drugs 1987;34(Suppl 3):139-148

w259

Crozier IG, Ikram H, Nicholls MG, Low CJS. Twenty-four hour profile of the hypotensive action of felodipine in essential hypertension. Cardiovasc Drugs Ther 1990;4:439-442

w260

Fagan TC. Blood pressure reduction and tolerability of felodipine ER in older and younger hypertensive patients. J Am Geriatr Soc 1997;45:712-717

w261

Hamilton DV, Barnes PC, Bowles RML, Rajaratnam DV, Comerford MB, Ginks WR, et al. Monotherapy with felodipine, a new calcium antagonist, in mild and moderate hypertension. J Cardiovasc Pharmacol 1987;10(supplS):S111-S113

w262

Hosie J, Mulder AW, Westberg B. Felodipine once daily in elderly hypertensives. J Hum Hypertens 1991;5:49-53

w263

Liedholm H, Melander A. A placebo-controlled dose-response study of felodipine extended release in hypertensive patients. J Cardiovasc Pharmacol 1989;14:109-113

w264

Madsen JK, Zachariae H, Pedersen EB. Effects of the calcium antagonist felodipine on renal aerodynamics, tubular sodium handling, and blood pressure in cyclosporin-treated dermatological patients. Nephrol Dial Transplant 1997;12:480-484

w265

McGrath BP, Watts RW, Elmfeldt DB. Clinical equivalence of two tablet formulations of felodipine. Eur J Clin Pharmacol 1995;49:169-172

w266

Pannarale G, Puddu PE, Monti F, Irace L, Bentivoglio M, Collauto F, et al. Twenty-four antihypertensive efficacy of felodipine 10 mg extended-release: the Italian inter-university study. J Cardiovasc Pharmacol 1996;27:255-261

w267

Porcellati C, Verdecchia P, Gatteschi C, Benemio G, Guerrieri M, Boldrini F, et al. Ambulatory blood pressure monitoring during sustained treatment with conventional and extended-release felodipine in mild-to-moderate hypertension. Eur J Clin Pharmacol 1989;37:555-557

w268

Bonaduce D, Canonico V, Petretta M, Forgione L, Ianniciello A, Cavallaro V, et al. Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study. Eur J Clin Pharmacol;1997;53:95-100

w269

van Ree JW, van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. J Hum Hypertens 1996;10:613-618

w270

Weber MA, Goldberg AI, Faisons EP, Lipschutz K, Shapiro DA, Nelson EB, et al. Extended-release felodipine in patients with mild to moderate hypertension. Clin Pharmacol Ther 1994;55:346-352

w271

Wester A, Lorimer AR, Westberg B. Felodipine extended release in mild to moderate hypertension. Curr Med Res Opin 1991;12:275-281

w272

Bossini A, Di Veroli C, Cavallotti G, Cagli V. Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo. Br J Clin Pharmac 1990;30:567-571

w273

Andersson OK, Persson B, Hedner T, Aurell M, Wysocki M. Blood pressure control and haemodynamic adaptation with the dihydropyridine calcium antagonist isradipine: a controlled study in middle-aged hypertensive men. J Hypertens 1989;7:465-469

w274

Arosio E, Pancera P, Priante F, Ribul M, De Marchi S, Lechi A. Effects of sustained-release isradipine on blood pressure and peripheral hemodynamics in hypertensive patients. Clin Ther 1993;15:705-713

w275

Arzilli E, Gandolfi E, Del Prato C, Innocenti P, Ponzanelli F, Gaiazza A, et al. Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study. Eur J Clin Pharmacol 1993;44:23-25

w276

Chrysant SG, Cohen M. Sustained blood pressure control with controlled-release isradipine. J Clin Pharmacol 1995;35:239-243

w277

Cléroux J, Yardley C, Marshall A, Coulombe D, Lacourcière Y. Antihypertensive and hemodynamic effects of calcium channel blockade with isradipine after acute exercise. Am J Hypertens 1992;5:84-87

w278

Fogari R, Malacco E, Tettamanti F, Gnemmi AE, Milani M. Evening vs morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring. Br J Clin Pharmacol 1993;35:51-54

w279

Holmes DG, Isradipine: a slow-release formulation given once daily controls blood pressure for 24h. Am J Hypertens 1993;6:74S-76S

w280

The Italian-Belgian Isradipine Study Group. Multicenter evaluation of the safety and efficacy of isradipine in hypertension. Am J Med 1989;86:94-97

w281

Kirch W, Burger KJ, Weidinger G, Welzel D. Efficacy and tolerability of the new calcium antagonist isradipine in essential hypertension. J Cardiovasc Pharmacol 1990;15(Suppl 1):S55-S59

w282

Low CJS, Foy SG, Chaudhary H, Crozier IG, Baskaranathan S, Ikram H. Twenty-four hour profile of the anti-hypertensive action of isradipine in essential hypertension. Blood Pressure 1993;2:59-61

w283

Nelson EB, Pool JL, Taylor AA. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium channel antagonist. Clin Pharmacol Ther 1986;40:694-7

w284

O’Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H. Effect of isradipine on in-vivo platelet function. Thromb Res 1997;86:363-371

w285

Rab SM, Mirza MA, Khan MH, Samad A, Ahmed M. Double-blind multicentre isradipine dose-confirmation study in Pakistan. Drugs 1990;40(Suppl 2):30-32

w286

Simonsen K. Dose-response relationship and incidence of adverse drug reactions with isradipine in patients with essential hypertension. Am J Med 1989;86:91-93

w287

Staessen J, Lijnen P, Fagard R, Hespel P, Tan WP, Devos P, et al. Effects of the new calcium entry blocker isradipine (NP 200-110) in essential hypertension. J Cardiovascular Pharmacol 1989;13:271-276

w288

Bremner AD, Fell PJ, Hosie J, James IGV, Saul PA, Taylor SH. Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. J Hum Hypertens 1993;7:79-81

w289

Carr AA, Bottini PB, Prisant LM, Mulligan S, Devane JG, Fisher L, et al. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. Am J Cardiol 1992;69(SupplE):28E-32E

w290

Corbin DOC, Wood DA, Macintyre CCA, Housley E. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud’s phenomenon. Eur Heart J 1986;7:165-170

w291

Eggertsen R, Hansson L. Effects of treatment with nifedipine and metoprolol in essential hypertension. Eur J Clin Pharmacol 1982;21:389-390

w292

Feig PU, Gibson L, MacCarthy EP, Pettis PP, Schwartz L. The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Clin Ther 1993;15:963-975

w293

Handa K, Mori T, Tanaka H, Takada Y, Matsunagga A, Kiyonaga A, et al. Administration of slow-release nifedipine does not affect lactate threshold, hormone release during exercise, and quality of life in normal subjects. Cardiovasc Drugs Ther 1992;6:85-90

w294

Zanchetti A. The 24-hour efficacy of a new once-daily formulation of nifedipine. Drugs 1994;48:23-31

w295

Landmark K, Dale J. Antihypertensive, haemodynamic and metabolic effects of nifedipine slow-release tablets in elderly patients. Acta Medica Scandinavica 1985;218:389-396

w296

Ozenne G, Moore ND, Leprevost A, Tardif C, Boismare F, Pasquis P, et al.Nifedipine in chronic bronchial asthma: a randomised double-blind crossover trial against placebo. Eur J Resp Dis 1985;67:238-243

w297

Patakas D, Maniki E, Tsāra V, Dascalōpōulou E. Nifedipine treatment of patients with bronchial asthma. J Allergy Clin Immunol 1987;79:959-963

w298

Salvetti A, Virdis A, Taddei S, Ambrosoli S, Caiazza A, Gandolfi E, et al. Trough:peak ratio of nifedipine gastrointestinal therapeutic system and nifedipine retard in essential hypertensive patients: an Italian multicentre study. J Hypertens 1996;14:661-667

w299

Sand J, Nordback I, Koskinen M, Matikainen M, Lindholm TS. Nifedipine for suspected type II sphincter of Oddi dyskinesia. Am J Gastroenterol 1993;4:530-535

w300

De Simone G, Ferrara LA, Fasano ML, Di Lorenzo L, Lauria R. Slow-release nifedipine versus placebo in the treatment of arterial hypertension. Jpn Heart J 1985;26:219-225

w301

Toal CB. Efficacy of a low dose nifedipine GITS (20 mg) in patients with mild to moderate hypertension. Can J Cardiol 1997;13:921-927

w302

Zachariah PK, Schwartz GL, Sheps SG, Schirger A, Carlson CA, Moore AG. Antihypertensive effects of a new sustained release formulation of nifedipine. J Clin Pharmacol 1990;30:1012-1019

w303

Harder S, Rietbrock S, Thűrmann P. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. Drug Res 1994;44:133-136

w304

Licata G, Scaglione R, Ganguzza A, Parrinello G, Costa R, Merlino G, et al. Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. Eur J Clin Pharmacol 1993;45:307-311

w305

Lorimer AR, Smedsrud T, Walker P, Tyler HM. A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. J Hum Hypertens 1989;3:191-196

w306

Lopez LM, Thorman AD, Mehta JL. Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus. Am J Cardiol 1990;66:1269-1271

w307

Mehta JL, Lopez LM, Vlachakis ND, Gradman AH, Nash DT, O’Connell MT, et al. Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. Am Heart J 1993;125:1704-1709

w308

Mroczek WJ, Burris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1988;12(Suppl 7):S79-84

w309

Webster J, Robb OJ, Jeffers TA, Scott AK, Petrie JC, Towler HM. Once daily amlodipine in the treatment of mild to moderate hypertension. Br J Clin Pharmacol 1987;24:713-719

w310

Frick MH, McGibney D, Tyler HM. Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension. J Cardiovasc Pharmacol 1988;12(Suppl 7):S76-S78

w311

Ahmed JH, Elliott HL, Hosie J, Rafish E, Reid JL. Effects of nicardipine on the metabolic responses to food and exercise. J Hum Hypertens 1992;6:139-144

w312

Bellett M, Pagny J-Y, Chatellier G, Corvol P, Ménard J. Evaluation of slow release nicardipine in essential hypertension by casual and ambulatory blood pressure measurements. Effects of acute versus chronic administration. J Hypertens 1987;5:599-604

w313

Cox JP, Ryan J, O’Brien E, O’Malley K. The effect of slow-release nicardipine on ambulatory and clinic blood pressure in mild hypertension. Br J Clin Pharmacol 1989;28:79-82

w314

Fagan TC, Tyler ED, Reitman MA, Kenley S, Weber MA. Sustained-release nicardipine in mild-to-moderate hypertension. Chest 1993;104:427-433

w315

Mazzola C, Borgnino C, Colombo D, Lissoni F, Serra G, Turri DR, et al. Antihypertensive and hemodynamic effects of slow-release nicardipine. Int J Clin Pharmacol Ther Toxicol 1988;26:503-508

w316

Salvetti A, Cardellino G, Pesenti M, Caiazza A, Ghisoni F, Del Prato C, et al. Antihypertensive effect of slow-release nicardipine. A placebo-controlled cross-over study. Eur J Clin Pharmacol 1989;36:439-442

w317

Soro S, Cocca A, Pasanisi F, Tommaselli A, de Simone G, Costantino G, et al. The effects of nicardipine on sodium and calcium metabolism in hypertensive patients: a chronic study. J Clin Pharmacol 1990;30:133-137

w318

Webster J, Petrie JC, Jeffers TA, Roy-Chaudhury P, Crichton W, Witte K, et al. Nicardipine sustained release in hypertension. Br J Clin Pharmacol 1991;32:433-439

w319

Omboni S, Zanchetti A. Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998;16:1831-1838

w320

Opie LH, Műller FO, Myburgh DP, Rosendorff C, Sareli P, Seedat YK, et al. Efficacy and tolerability of nisoldipine coat-core formulation in the treatment of essential hypertension. Am J Hypertens 1997;10:250-260

w321

Lijnen P, Petrov V. Blood pressure and cationic transport systems during combined calcium channel blocker and calcium administration in males. Methods Find Exp Clin Pharmacol 1996;18:287-294

w322

Morris AD, Donnelly R, Connell JMC, Reid JL. Effects of the calcium antagonist lacidipine on insulin sensitivity in essential hypertension. Horm Metab Res 1994;26:257-259

w323

Rizzini P, Castello C, Salvi S, Recchia G. Efficacy and safety of lacidipine, a new long-lasting calcium antagonist, in elderly hypertensive patients. J Cardiovasc Pharmacol 1991;17(Suppl 4):S39-S44

w324

Ueda S, Donnelly R, Panfilov V, Morris AD, Elliott HL. Lacidipine: effects on vascular pressure responses throughout the dosage interval in normotensive subjects. Br J Clin Pharmacol 1998;46:127-132

w325

Lacourcière Y, Poirier L, Lefebvre J, Burford RG. Clinical efficacy of force titrated doses of diltiazem extended-release. Am J Hypertens 1995;8:282-286

w326

Felicetta JV, Serfer HM, Cutler NR, Comstock TJ, Huber GL, Weir MR, et al. A dose-response trial of once-daily diltiazem. Am Heart J 1992;123:1022-1026

w327

Fiddes R, Heym H, Hilty W, Lewin AJ, Codispoti J, McNally C, et al. Blood pressure control with diltiazem XR, a novel extended-release formulation of diltiazem HCL, in mature and elderly hypertensive patients. Clin Ther 1994;16:209-221

w328

Dupont AG, Coupez JM, Jensen P, Coupez-Lopinot R, Schoors DF, Hermanns P, et al. Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension. Cardiovasc Drugs Ther 1991;5:701-708

w329

Meeves SG, Park GD. The use of confidence intervals to describe the precision of trough/peak ratios for diltiazem CD in the treatment of hypertension. J Clin Pharmacol 1994;34:231-235

w330

Meeves S, Hafner K, Park G, Weber M. Three-period crossover trial with ambulatory blood pressure monitoring for evaluating antihypertensive therapy. Am Heart J 1995;130:841-848

w331

Pool PE, Seagren SC, Salel AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized, double-blind, placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985;56(supplH):86H-91H

w332

Whelton A, Eff J, Magner DJ. Sustained antihypertensive activity of diltiazem SR: double-blind, placebo controlled study with 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1992;32:808-815

w333

Woehler TR, Eff J, Graney W, Heald D, Ziemniak J, Magner D. Multicenter evaluation of the efficacy and safety of sustained-release diltiazem hydrochloride for the treatment of hypertension. Clin Ther 1992;14:148-157

w334

Van Merode T, Van Bortel L, Smeets FAM, Bőhm R, Mooij J, Rahn KH, et al. The effects of verapamil on carotid artery distensibility and cross-sectional compliance in hypertensive patients. J Cardiovasc Pharmacol 1990;15:109-113

w335

Hedbäck B, Hermann LS. Antihypertensive effect of verapamil in patients with newly discovered mild to moderate essential hypertension. Acta Medica Scandinavica Suppl 1984;681:129-35

w336

Kimose H-H, Bagger JP, Aagaard MT, Paulsen PK. Placebo-controlled, double-blind study of the effect of verapamil in intermittent claudication. Angiology1990;41:595-598

w337

Carr AA, Bottini PB, Prisant LM, Fisher LD, Devane JG, O’Brien DE, Rhoades RB. Once-daily verapamil in the treatment of mild-to-moderate hypertension: a double-blind placebo-controlled dose-ranging study. J Clin Pharmacol 1991;31:144-150

w338

McMahon FG, Reder RF. The relationship of dose to the antihypertensive response of verapamil-sustained release in patients with mild to moderate essential hypertension. J Clin Pharmacol 1989;29:1003-1007

w339

Neutel JM, Alderman M, Anders RJ, Weber MA. Novel delivery system for verapamil designed to achieve maximal blood pressure control during the early morning. Am Heart J 1996;132:1202-1206

w340

Corea L, Bentivoglio M, Berioli S, Bianchini C, Savino K, Sardina M. Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind placebo-controlled study with 24-hour ambulatory blood pressure monitoring. Cardiovascular Drugs Therapy 1990;4:1501-1508

w341

Lewis GRJ, Morley KD, Lewis BM, Bones PJ. The treatment of hypertension with verapamil. NZ Med J 1978;87:351-354

w342

Van Bortel LMAB, Schiffers PMH, Bőhm ROB, Mooij JMV, Rahn KH, Struyker Boudier HAJ. The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients. Eur J Clin Pharmacol 1990;39(Suppl 1):S39-S40

w343

White WB, Anders RJ, MacIntyre JM, Black HR, Sica DA. Nocturnal dosing of a novel delivery system of verapamil for systemic hypertension. Am J Cardiol 1995;76:375-380